# Protein Degradation and Inhibitors

**Type:** Topics  
**Canonical URL:** https://scholariq.org/topics/protein-degradation-and-inhibitors/

## Facts

| Field | Value |
| --- | --- |
| Description | This cluster of papers focuses on the targeted degradation of specific proteins, particularly through the use of BET bromodomain inhibitors and PROTACs. The research explores the therapeutic potential of this approach, with a focus on histone recognition, small molecule inhibitors, and the role of epigenetic readers in transcriptional regulation. Additionally, it investigates the use of cereblon-dependent degradation and its implications for drug discovery. |
| Domain | Life Sciences |
| Field | Biochemistry, Genetics and Molecular Biology |
| OpenAlex ID | t12534 |
| Works | 133 |

## Topic papers all

Showing 15 of 133.

- [Histone H3K27ac separates active from poised enhancers and predicts developmental state](https://scholariq.org/papers/histone-h3k27ac-separates-active-from-poised-enhancers-and-predicts/)
- [International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma](https://scholariq.org/papers/international-myeloma-working-group-consensus-criteria-for-response-and-minimal/)
- [Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer](https://scholariq.org/papers/niraparib-in-patients-with-newly-diagnosed-advanced-ovarian-cancer/)
- [Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells](https://scholariq.org/papers/lenalidomide-causes-selective-degradation-of-ikzf1-and-ikzf3-in-multiple-myeloma/)
- [Catalytic in vivo protein knockdown by small-molecule PROTACs](https://scholariq.org/papers/catalytic-in-vivo-protein-knockdown-by-small-molecule-protacs/)
- [Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4](https://scholariq.org/papers/hijacking-the-e3-ubiquitin-ligase-cereblon-to-efficiently-target-brd4/)
- [Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead](https://scholariq.org/papers/lessons-in-protac-design-from-selective-degradation-with-a-promiscuous-warhead/)
- [Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma](https://scholariq.org/papers/lenalidomide-bortezomib-and-dexamethasone-combination-therapy-in-patients-with/)
- [PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer](https://scholariq.org/papers/protac-induced-bet-protein-degradation-as-a-therapy-for-castration-resistant/)
- [Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma](https://scholariq.org/papers/lenalidomide-and-dexamethasone-in-transplant-ineligible-patients-with-myeloma/)
- [The role of ubiquitination in tumorigenesis and targeted drug discovery](https://scholariq.org/papers/the-role-of-ubiquitination-in-tumorigenesis-and-targeted-drug-discovery/)
- [Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer](https://scholariq.org/papers/dynamic-reprogramming-of-the-kinome-in-response-to-targeted-mek-inhibition-in/)
- [Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial](https://scholariq.org/papers/daratumumab-lenalidomide-bortezomib-and-dexamethasone-for-transplant-eligible/)
- [Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers](https://scholariq.org/papers/synthetic-lethality-by-targeting-ezh2-methyltransferase-activity-in-arid1a/)
- [The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study](https://scholariq.org/papers/the-advantages-of-targeted-protein-degradation-over-inhibition-an-rtk-case-study/)

## Topic primary papers

Showing 15 of 51.

- [Catalytic in vivo protein knockdown by small-molecule PROTACs](https://scholariq.org/papers/catalytic-in-vivo-protein-knockdown-by-small-molecule-protacs/)
- [Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4](https://scholariq.org/papers/hijacking-the-e3-ubiquitin-ligase-cereblon-to-efficiently-target-brd4/)
- [Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead](https://scholariq.org/papers/lessons-in-protac-design-from-selective-degradation-with-a-promiscuous-warhead/)
- [PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer](https://scholariq.org/papers/protac-induced-bet-protein-degradation-as-a-therapy-for-castration-resistant/)
- [The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study](https://scholariq.org/papers/the-advantages-of-targeted-protein-degradation-over-inhibition-an-rtk-case-study/)
- [Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer](https://scholariq.org/papers/response-and-resistance-to-bet-bromodomain-inhibitors-in-triple-negative-breast/)
- [BET inhibitor resistance emerges from leukaemia stem cells](https://scholariq.org/papers/bet-inhibitor-resistance-emerges-from-leukaemia-stem-cells/)
- [Combinatorial Roles of the Nuclear Receptor Corepressor in Transcription and Development](https://scholariq.org/papers/combinatorial-roles-of-the-nuclear-receptor-corepressor-in-transcription-and/)
- [A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader](https://scholariq.org/papers/a-chemoproteomic-approach-to-query-the-degradable-kinome-using-a-multi-kinase/)
- [Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development](https://scholariq.org/papers/mapping-the-degradable-kinome-provides-a-resource-for-expedited-degrader/)
- [Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials](https://scholariq.org/papers/recent-advances-in-targeting-the-undruggable-proteins-from-drug-discovery-to/)
- [Integrated genomic characterization of IDH1-mutant glioma malignant progression](https://scholariq.org/papers/integrated-genomic-characterization-of-idh1-mutant-glioma-malignant-progression/)
- [The bromodomain protein Brd4 insulates chromatin from DNA damage signalling](https://scholariq.org/papers/the-bromodomain-protein-brd4-insulates-chromatin-from-dna-damage-signalling/)
- [HIP1R targets PD-L1 to lysosomal degradation to alter T cell–mediated cytotoxicity](https://scholariq.org/papers/hip1r-targets-pd-l1-to-lysosomal-degradation-to-alter-t-cell-mediated/)
- [Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles](https://scholariq.org/papers/enhanced-efficacy-of-combined-temozolomide-and-bromodomain-inhibitor-therapy-for/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.